Novartis' Cosentyx Recommended for Adolescent Hidradenitis Suppurativa Treatment

The European Medicines Agency's CHMP has issued a positive opinion for Novartis' Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa in adolescents aged 12 and older. This recommendation is a significant step toward expanding treatment options for younger patients with this chronic inflammatory skin condition who have not responded to existing therapies.